Our goal is to bring to the market the first IVDD for the early detection of ischemia

GlyCardial Diagnostics is a spin-off company of the ICCC- IR-Hospital de la Santa Creu i Sant Pau and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event.

The novelty and the potential impact of the Apo J-Glyc project has been recognized by several entities at a national and international level.